Bio-Rad Laboratories, a global leader in life sciences research and clinical diagnostic products, today announced the launch of the QX700 system-compatible Vericheck ddPCR kit portfolio for critical quality control (QC) workflows in advanced cell and gene therapy development and other biopharmaceutical applications. This portfolio includes Vericheck ddPCR Mycoplasma Detection, Empty-Full Capsid, Replication Competent Lentivirus, CHO Residual DNA Quantification, and E. coli Residual DNA Quantification Kit.
Vericheck ddPCR™ Kit. Image credit: Bio-Rad Laboratories, Inc.
The newly launched kits expand Bio-Rad’s existing ddPCR platform portfolio to provide ready-to-use, application-focused, validated kits for critical QC workflows in biopharmaceuticals, including cell and gene therapy applications. Bio-Rad’s QX700 platform enables seven-color multiplexing and has the ability to process up to 384 reactions in approximately 2.5 hours with minimal input volume, continuous loading capabilities, and easy-to-use software for streamlined data interpretation. By combining the performance of the QX700 system with the Vericheck kit, researchers can generate accurate, reproducible, and faster results for product development, product safety, and quality.
In the development and manufacturing of advanced therapeutics, QC testing is critical to ensuring product safety and efficacy. The new Vericheck kit provides developers with a complete, easy-to-access solution for high-priority QC testing needs, offering validated workflows that improve confidence in vector characterization and contamination detection, including testing for replication-competent virus and quantifying residual host cell DNA.
Our expanded range of Vericheck ddPCR kits, combined with the power of the QX700 platform, provides a validated workflow with unparalleled accuracy and sensitivity, enabling scalable, streamlined workflows and faster time to actionable results. By expanding the capabilities of the QX700 platform through the development of this new Vericheck kit, Bio-Rad continues its commitment to supporting the development and manufacturing of safer, more efficient advanced therapeutics. ”
Stephen Kulisch, Vice President of Marketing, Digital Biology Group, Bio-Rad
sauce:
Bio-Rad Laboratories, Inc.
